168 related articles for article (PubMed ID: 28361167)
1. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
[TBL] [Abstract][Full Text] [Related]
3. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
[TBL] [Abstract][Full Text] [Related]
5. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
6. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
[TBL] [Abstract][Full Text] [Related]
10. What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
Davies RS; Smith C; Button MR; Tanguay J; Barber J; Palaniappan N; Staffurth J; Lester JF
Anticancer Res; 2015 Oct; 35(10):5615-21. PubMed ID: 26408734
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Benoist GE; van Oort IM; Smeenk S; Javad A; Somford DM; Burger DM; Mehra N; van Erp NP
Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
[TBL] [Abstract][Full Text] [Related]
12. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O; De Giorgi U; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Macrini S; Messina C; Giordano M; Alesini D; Zustovich F; Fraccon AP; Vicario G; Conteduca V; Maines F; Galligioni E
BJU Int; 2015 May; 115(5):764-71. PubMed ID: 24988879
[TBL] [Abstract][Full Text] [Related]
13. Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone.
Dubinsky S; Thawer A; McLeod AG; McFarlane TRJ; Emmenegger U
Support Care Cancer; 2019 Sep; 27(9):3209-3217. PubMed ID: 31073853
[TBL] [Abstract][Full Text] [Related]
14. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
15. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
20. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
Detti B; D'Angelillo RM; Ingrosso G; Olmetto E; Francolini G; Triggiani L; Bruni A; Borghesi S; Fondelli S; Carfagno T; Santini R; Santoni R; Trodella LE; Livi L
Anticancer Res; 2017 Jul; 37(7):3717-3722. PubMed ID: 28668865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
